Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 2Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 21Lung Neoplasms 7Neoplasms 5Neoplasm Metastasis 5Adenocarcinoma of Lung 5Melanoma 3Glioblastoma 3Carcinoma 3cMET-dysregulated Advanced Solid Tumors 2Sarcoma 2Neoplasms by Site 2Neoplasms by Histologic Type 2Hematologic Neoplasms 2Gliosarcoma 2Colorectal Neoplasms 2cMET Dysegulation Advanced Solid Tumors 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Noonan Syndrome 6 1Neuroblastoma 1Malignant Non-small Cell Neoplasm of Lung Stage IV 1Lymphoproliferative Disorders 1Liver Neoplasms 1Laryngeal Diseases 1Kidney Neoplasms 1Hepatic Impairment 1Glioma 1EGFR-mutant Non-small Cell Lung Cancer 1

Interventions

Temozolomide 393Radiotherapy 196Bevacizumab 156Radiation 77Magnetic Resonance Spectroscopy 68Lomustine 47Surgical Procedures, Operative 42Carmustine 41pembrolizumab 39Irinotecan 38Nivolumab 32Specimen Handling 27Carboplatin 27Radiosurgery 24Erlotinib Hydrochloride 24Chemotherapy, Adjuvant 23Radiotherapy, Intensity-Modulated 22Drug Therapy 20Cyclophosphamide 20Aminolevulinic Acid 20O(6)-benzylguanine 17sargramostim 16Radiotherapy, Conformal 15temsirolimus 14Granulocyte-Macrophage Colony-Stimulating Factor 14Everolimus 14Vorinostat 13Sorafenib 13poly ICLC 12atezolizumab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Glioblastoma × capmatinib × Clear all
NCT02386826 2023-09-21

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

SCRI Development Innovations, LLC

Phase 1 Completed
65 enrolled
CNSGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Glioblastoma, Colorectal Neoplasms, Gliosarcoma

NCT01324479 2020-12-19

Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors

Novartis

Phase 1 Completed
131 enrolled
CNSThoracic

Carcinoma, Non-Small-Cell Lung, Glioblastoma

NCT01870726 2018-05-30

Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma

Novartis

Phase 1/2 Terminated
43 enrolled 22 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡